Pyxis Oncology (PYXS) Retained Earnings (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Retained Earnings of $53000.0 for Q4 2025, down 99.99% year-over-year from $484.1 million in Q4 2024, and up 100.01% quarter-over-quarter from -$425.1 million in Q3 2025.
Pyxis Oncology (PYXS) Retained Earnings (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Retained Earnings for 6 consecutive years, with $53000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings fell 99.99% year-over-year to $53000.0; the TTM figure through Dec 2025 stood at $53000.0 (down 99.99% YoY), while the FY2025 annual figure was $53000.0, down 99.99% from the prior year.
- Retained Earnings improved to $53000.0 in Q4 2025 per PYXS's latest filing, from -$425.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $484.1 million in Q4 2024 and bottomed at -$425.1 million in Q3 2025.
- Historically, Retained Earnings has averaged $83.6 million across 5 years, with a median of $176.5 million in 2021.
- Annual changes were most pronounced in 2021 — Retained Earnings jumped 363816.49% — and 2025, when it slumped 188.33%.
- Pyxis Oncology's Retained Earnings stood at $353.0 million in 2021, then gained by 5.73% to $373.2 million in 2022, then climbed by 10.34% to $411.8 million in 2023, then gained by 17.55% to $484.1 million in 2024, then plunged by 99.99% to $53000.0 in 2025.
- Business Quant data shows PYXS's Retained Earnings at $53000.0 in Q4 2025, -$425.1 million in Q3 2025, and -$403.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | 503.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 503.18 Mn |
| Dec 31, 2025 | 53,000.00 |
| Sep 30, 2025 | -425.07 Mn |
| Jun 30, 2025 | -403.10 Mn |
| Mar 31, 2025 | -384.70 Mn |
| Dec 31, 2024 | 484.08 Mn |
| Sep 30, 2024 | 481.26 Mn |
| Jun 30, 2024 | 476.62 Mn |
| Mar 31, 2024 | -289.50 Mn |
| Dec 31, 2023 | 411.82 Mn |
| Sep 30, 2023 | 408.64 Mn |
| Jun 30, 2023 | -247.58 Mn |
| Mar 31, 2023 | -231.70 Mn |
| Dec 31, 2022 | 373.23 Mn |
| Sep 30, 2022 | 365.05 Mn |
| Jun 30, 2022 | -148.70 Mn |
| Mar 31, 2022 | 356.58 Mn |
| Dec 31, 2021 | 353.00 Mn |
| Sep 30, 2021 | -74.90 Mn |
| Dec 31, 2020 | 97,000.00 |